Caribou Biosciences, Inc. · NASDAQ:CRBU
Caribou Biosciences — Technical Presentation (July 2023)
37 slides from Caribou Biosciences's technical presentation, Jul 13, 2023
Slide 1: CB-010 clinical program update
CB-010 clinical program update Transformative genome-edited therapies for patients July 13, 2023
Slide 2: Forward-looking statements
2 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These fo
Slide 3: The future of CAR-T cell therapies is off-the-shelf
The future of CAR-T cell therapies is off-the-shelf ANTLER dose escalation data Rachel Haurwitz, PhD President & CEO Caribou Biosciences, Inc.
Slide 4: Today's guest
4 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Today’s guest Deputy chair and associate professor in the department of lymphoma/myeloma The University of Texas MD Anderson Cancer Center Loretta J. Nastoupil, MD
Slide 5: With gratitude for patients, caregivers, investigators
5 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. With gratitude for patients, caregivers, investigators Clinicaltrials.gov NCT#04637763 • University of Texas MD Anderson Cancer Center • Chao Family Comprehensive Cancer Center / University of California Irvine, Orange • On
Slide 6: CB-010 dose escalation data rival approved autologous CAR-T therapies
6 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. 94% overall response rate (ORR)1 69% complete response (CR) rate2 CB-010 dose escalation data rival approved autologous CAR-T cell therapies 44% complete response (CR) rate ≥6 months3 1 94% ORR measures number of patients (
Slide 7: CB-010 drives durable CRs that rival autologous CAR-T cell therapies
7 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 drives durable CRs that rival autologous CAR-T cell therapies 94% 69% 44% 50% 32% 30% 72% 51% 36% 73% 54% 35% Overall response rate (ORR) Complete response (CR) rate CR rate at 6 months CB-010 Kymriah Yescarta Breyan
Slide 8: Patients shouldn't have to wait for treatment
8 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Patients shouldn’t have to wait for treatment Autologous therapy N=1 Manufacturing, product failure identification Bridging therapyLeukapheresis Queuing, leukapheresis scheduling Sample shipment Product shipment Allogeneic
Slide 9: Pipeline: allogeneic cell therapies targeting oncology indications
9 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Pipeline: allogeneic cell therapies targeting oncology indications IND: investigational new drug; RMAT: Regenerative Medicine Advanced Therapy 1 Phase 3 may not be required if Phase 2 is pivotal 2 Also known as CD371 3 AbbV
Slide 10: CB-010 has a PD-1 KO designed to reduce T cell exhaustion
10 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 has a PD-1 KO designed to reduce T cell exhaustion CAR: chimeric antigen receptor; KO: knockout; CD: cluster of differentiation; chRDNA: CRISPR hybrid RNA-DNA; CRISPR: clustered regularly interspaced short palindrom
Slide 11: ANTLER Phase 1 trial dose escalation data CB-010
ANTLER Phase 1 trial dose escalation data CB-010 Loretta J. Nastoupil, MD Deputy chair and associate professor in the department of lymphoma/myeloma The University of Texas MD Anderson Cancer Center
Slide 12: Disclosures
12 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Disclosures • LJN has received honorarium for participation in advisory boards or consulting from Abbvie, ADC Therapeutics, Astra Zeneca, BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech/Roche, Genmab, Gilead/K
Slide 13: CB-010 ANTLER Phase 1 trial: dose expansion in 2L LBCL underway
13 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 ANTLER Phase 1 trial: dose expansion in 2L LBCL underway NCT04637763 1 Subtypes include: DLBCL, HGBL, tFL, PMBCL, FL, MZL, MCL (Note, FL subtype is aggressively behaving, with POD24 (high risk)) 2 LBCL subtypes incl
Slide 14: Patients in ANTLER all had aggressive r/r B-NHL
14 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Patients in ANTLER all had aggressive r/r B-NHL Patients’ baseline and disease characteristics DLBCL: diffuse large B cell lymphoma; FL: follicular lymphoma; HGBL: high-grade B cell lymphoma; MCL: mantle cell lymphoma; MZL
Slide 15: CB-010 has generally well-tolerated safety profile
15 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 has generally well-tolerated safety profile No DLTs at dose level 2 or dose level 3, no Grade 3+ CRS, no GvHD observed (N=16) AE: adverse event; CRS: cytokine release syndrome; DLT: dose-limiting toxicity; GvHD: gra
Slide 16: CB-010 ANTLER dose escalation efficacy assessment
16 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. DLBCL: diffuse large B cell lymphoma; FL: follicular lymphoma; HGBL: high-grade B cell lymphoma; MCL: mantle cell lymphoma; MZL: marginal zone lymphoma; PMBCL: primary mediastinal large B cell lymphoma 1 Aggressively behav
Slide 17: Subgroup efficacy profile supports 2L LBCL clinical development
17 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Subgroup efficacy profile supports 2L LBCL clinical development r/r B-NHL r/r LBCL2 2L LBCL3 Endpoints N, (%) All patients (N=16) Subgroup (N=10) Subgroup (N=4) Overall response rate (ORR)1 15 (94%) 9 (90%) 4 (100%) Comple
Slide 18: Fireside chat
Fireside chat CARIBOU > BIOSCIENCES
Slide 19: Fireside chat with Dr. Nastoupil
19 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Fireside chat with Dr. Nastoupil President and CEO Caribou Biosciences Rachel Haurwitz, PhD Deputy chair and associate professor in the department of lymphoma/myeloma The University of Texas MD Anderson Cancer Center Loret
Slide 20: Q&A
Q&A CARIBOU > BIOSCIENCES
Slide 21: Open to your questions
21 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Open to your questions President and CEO Rachel Haurwitz, PhD CMO Syed Rizvi, MD Caribou Biosciences Steve Kanner, PhD CSO Loretta J. Nastoupil, MD Deputy chair and associate professor in the department of lymphoma/myeloma
Slide 22: Closing remarks
Closing remarks Rachel Haurwitz, PhD President & CEO Caribou Biosciences, Inc.
Slide 23: With gratitude for patients, caregivers, investigators
23 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. With gratitude for patients, caregivers, investigators Clinicaltrials.gov NCT#04637763 • University of Texas MD Anderson Cancer Center • Chao Family Comprehensive Cancer Center / University of California Irvine, Orange • O
Slide 24: Dose escalation data support ANTLER dose expansion
24 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Dose escalation data support ANTLER dose expansion 1 94% ORR measures number of patients (15 of 16) achieving either a CR or partial response (PR) at any time point after treatment with CB-010. 2 69% CR rate measures the n
Slide 25: The momentum continues in 2023
25 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. The momentum continues in 2023 IND: investigational new drug, RMAT: Regenerative Medicines Advanced Therapy 1 Preliminary cash, cash equivalents, and marketable securities as of June 30, 2023; includes $25M Pfizer investme
Slide 26: Thank you
Thank you https://cariboubio.com info@cariboubio.com
Slide 27: Appendix
Appendix CARIBOU > BIOSCIENCES
Slide 28: Potential to address high unmet medical need in 2L LBCL
28 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Potential to address high unmet medical need in 2L LBCL 71% 10% 11% 5% HGBL PMBCL tFL 3% tCLL ~32.4K patients DLBCL ~32.4K patientsDiagnosed 1L ~30.8K patients 2L ~10.0K patients 3L ~4.4K patients LBCL patient treatment jo
Slide 29: CB-010 ANTLER dose escalation efficacy assessment by dose level
29 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 ANTLER dose escalation efficacy assessment Overall, r/r, and 2L LBCL subgroups, by dose level 1 Certain patients converted from a CR or partial response (PR) to progressive disease (PD) at various assessment time po
Slide 30: CB-010's responses rival autologous CAR-T cell therapies
30 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. CB-010’s responses rival autologous CAR-T cell therapies Sources / patients enrolled Kymriah: USPI, NCT02445248, Schuster NEJM 2019 / DLBCL NOS (78%) and tFL (22%) Yescarta: USPI, NCT02348216 / Locke, et al, AACR 2017 ZUMA
Slide 31: CB-010 dose escalation data compare favorably to other allogeneic CAR-T approach
31 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 dose escalation data compare favorably to other allogeneic CAR-T cell therapy approach Source: Allogene corporate presentation (June 2023) and Allogene R&D Showcase (November 2022) 1 Certain patients converted from
Slide 32: CB-010 is generally well tolerated
32 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 is generally well tolerated Treatment-emergent adverse events (TEAE) 1 TEAEs are defined as adverse events (AEs) with a start date on or after the CB-010 infusion date. 2 Encephalopathy and Grade 4 ICANS events were
Slide 33: CB-010 demonstrated differentiated, long-term antitumor activity in preclinical studies
33 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 demonstrated differentiated, long-term antitumor activity in preclinical studies Lau E, et al. Cytotherapy. 2023;25(7):750 • NALM-6/PD-L1+ B-ALL tumors were established by IV engraftment for 23 days (Day -1) • A sin
Slide 34: Allogeneic CAR-T cell manufacturing process overview for CB-010
34 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. cGMP starting material Genetic modification via chRDNA and AAV Gene-modified CAR-T cells In vitro expansion of edited donor T cells Removal of residual TCR+ cells Final formulation & cryopreservation Treatment Anti-TCR mic
Slide 35: Caribou is a leader in the allogeneic CAR-T cell space
35 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Caribou is a leader in the allogeneic CAR-T cell space with a platform of genome-edited cell therapies 3 Edits 4 Edits 5 Edits CB-010 B cell non-Hodgkin lymphoma PD-1 KO Anti-CD19 CAR TCR KO CB-011 Multiple myeloma B2M–HLA
Slide 36: Caribou's technologies offer broad applications
36 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Caribou’s technologies offer broad applications to enable transformational therapies Initial focus on allogeneic cell therapies with: Potential for improved antitumor activity through diverse genome-editing strategies Chec
Slide 37: Experienced management team
37 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. Barbara McClung, JD Chief legal officer and corporate secretary Steve Kanner, PhD Chief scientific officer Jason O’Byrne Chief financial officer Rachel Haurwitz, PhD President and CEO Director Ruhi Khan Chief business offi
Caribou Biosciences — Technical Presentation (July 2023) on 6ix